Crossmark

Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies

Crossref DOI link: https://doi.org/10.1186/s12931-024-02994-w

Published Online: 2024-10-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reinders, Stefan

Didden, Eva-Maria

Ong, Rose
Funding

Funding for this research was provided by:

Actelion Pharmaceuticals Ltd, a Johnson and Johnson company..
License Information

Text and Data Mining valid from 2024-10-16

Version of Record valid from 2024-10-16
More Information

Article History

Received: 13 December 2023

Accepted: 28 September 2024

First Online: 16 October 2024

Declarations

:

: Not applicable.

: Not applicable.

: SR has received consultancy fees from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company. RO and EMD are employees of Actelion Pharmaceuticals Ltd, a Johnson & Johnson company.

Document is current

Any future updates will be listed below